Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do ...

Brian Peters started his new role as SVP of the AI Squared division at Apimeds Pharmaceuticals. Pharma market research firm Konovo named Tim Albury as CFO. Tenpoint Therapeutics announced the ...

Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

A leading Chinese expert has noted the importance of implementing innovative digital assessment and monitoring systems to ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune ...